Koda Health Secures $7 Million Series A to Accelerate Nationwide Expansion in Advance Care Planning

Koda Health, a Houston-based digital health startup that focuses on advance care planning (ACP), has closed a US$ 7 million Series A funding round — a milestone that underscores growing investor confidence in scalable, patient-centered care technologies. The round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center.

Koda Health provides an AI-enhanced, EMR-integrated patient decision-support platform that enables health systems, payers, and providers to scale “goals-of-care” conversations and enables patients to complete legally valid advance directives, do-not-resuscitate (DNR) orders, and medical power-of-attorney documents — often asynchronously, and sometimes in multiple languages.

With this new capital infusion, Koda Health plans to expand its national footprint, ramp up hiring across engineering, clinical strategy, and customer-success teams, and accelerate the development of new product lines. The funding will also support enhancement of the platform’s capacity to serve large health systems and payers at scale.

This Series A builds on prior rounds: in 2024, Koda closed a Seed+ round led by Ecliptic Capital, with strategic investments from Memorial Hermann Health System, AARP and the Texas Medical Center Venture Fund; and earlier in 2022, it secured seed-level capital — helping launch the platform and begin partnerships with healthcare institutions.

Since its founding in 2020 by a team that met through Texas Medical Center’s Biodesign program, Koda Health has grown from a small team into a national platform supporting over one million patients across the United States. Its offerings now include condition-specific care-planning tools — for instance, a “Kidney Action Planning” solution tailored for patients with chronic kidney disease (CKD), helping them navigate treatment decisions in alignment with personal values.

The new funding arrives at a time when regulatory and policy shifts are favoring value-based care models and greater institutional support for advance care planning. With health systems under rising pressure to deliver care that respects patient preferences while containing costs, Koda’s mission — to make serious-illness planning accessible, equitable, and integrated — aligns closely with emerging industry priorities.

With substantial backing from both venture-capital and healthcare-system investors, and increased demand from payers and providers seeking scalable ACP solutions, Koda Health appears well-positioned to expand its impact. The funding will likely accelerate its growth trajectory as it seeks to embed its care-planning platform more deeply into U.S. health systems and broaden access to high-quality, goal-concordant serious-illness care.